Marlène Rio

Marlène Rio

Auto-generated profile, based on publicly available information

Marlène Rio

Fédération de Génétique, Hôpital Necker-Enfants Malades

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2015 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
YCYanick J. Crow
Yanick J. Crow
DCDiana S. Chase
Diana S. Chase
JSJohanna Lowenstein Schmidt
Johanna Lowenstein Schmidt
MSMarcin Szynkiewicz
Marcin Szynkiewicz
GFGabriella M.A. Forte
Gabriella M.A. Forte
GRGillian I. Rice
Gillian I. Rice

1 April 2004 in Journal of Medical Genetics
Verified
Journal Article
Open access
PDF file
CSC Shaw-Smith
C Shaw-Smith
RRR Redon
R Redon
LRL Rickman
L Rickman
MRM Rio
M Rio
LWL Willatt
L Willatt
NCN P Carter
N P Carter
The underlying causes of learning disability and dysmorphic features in many patients remain unidentified despite extensive investigation. Routine karyotype analysis is not sensitive enough to detect subtle chromosome rearrangements (less than 5 Mb). The presence of subtle DNA copy number changes was investigated by array-CGH in 50 patients with learning disability and dysmorphism, employing a DNA microarray constructed from large insert clones spaced at approximately 1 Mb intervals across the genome. Twelve copy number abnormalities were identified in 12 patients (24% of the total): seven deletions (six apparently de novo and one inherited from a phenotypically normal parent) and five duplications (one de novo and four inherited from phenotypically normal parents). Altered segments ranged in size from those involving a single clone to regions as large as 14 Mb. No recurrent deletion or duplication was identified within this cohort of patients. On the basis of these results, we anticipate that array-CGH will become a routine method of genome-wide screening for imbalanced rearrangements in children with learning disability.


14 September 2007 in Journal of Medical Genetics
Verified
Journal Article
Closed access
PDF file
CNCaroline Nava
Caroline Nava
NHNadine Hanna
Nadine Hanna
CMCaroline Michot
Caroline Michot
SPSabrina Pereira
Sabrina Pereira
NPNathalie Pouvreau
Nathalie Pouvreau
HCHélène Cavé
Hélène Cavé
Cardio-facio-cutaneous (CFC) syndrome, Noonan syndrome (NS), and Costello syndrome (CS) are clinically related developmental disorders that have been recently linked to mutations in the RAS/MEK/ERK signalling pathway. This study was a mutation analysis of the KRAS, BRAF, MEK1 and MEK2 genes in a total of 130 patients (40 patients with a clinical diagnosis of CFC, 20 patients without HRAS mutations from the French Costello family support group, and 70 patients with NS without PTPN11 or SOS1 mutations). BRAF mutations were found in 14/40 (35%) patients with CFC and 8/20 (40%) HRAS-negative patients with CS. KRAS mutations were found in 1/40 (2.5%) patients with CFC, 2/20 (10%) HRAS-negative patients with CS and 4/70 patients with NS (5.7%). MEK1 mutations were found in 4/40 patients with CFC (10%), 4/20 (20%) HRAS-negative patients with CS and 3/70 (4.3%) patients with NS, and MEK2 mutations in 4/40 (10%) patients with CFC. Analysis of the major phenotypic features suggests significant clinical overlap between CS and CFC. The phenotype associated with MEK mutations seems less severe, and is compatible with normal mental development. Features considered distinctive for CS were also found to be associated with BRAF or MEK mutations. Because of its particular cancer risk, the term “Costello syndrome” should only be used for patients with proven HRAS mutation. These results confirm that KRAS is a minor contributor to NS and show that MEK is involved in some cases of NS, demonstrating a phenotypic continuum between the clinical entities. Although some associated features appear to be characteristic of a specific gene, no simple rule exists to distinguish NS from CFC easily.

22 December 2009 in Circulation
Verified
Journal Article
Closed access
PDF file
DADavid Attias
David Attias
CSChantal Stheneur
Chantal Stheneur
CRCarine Roy
Carine Roy
GCGwenaëlle Collod-Béroud
Gwenaëlle Collod-Béroud
DDDelphine Detaint
Delphine Detaint
GJGuillaume Jondeau
Guillaume Jondeau
Background— TGFBR2 mutations were recognized recently among patients with a Marfan-like phenotype. The associated clinical and prognostic spectra remain unclear. Methods and Results— Clinical features and outcomes of 71 patients with a TGFBR2 mutation (TGFBR2 group) were compared with 50 age- and sex-matched unaffected family members (control subjects) and 243 patients harboring FBN1 mutations (FBN1 group). Aortic dilatation was present in a similar proportion of patients in both the TGFBR2 and FBN1 groups (78% versus 79%, respectively) but was highly variable. The incidence and average age for thoracic aortic surgery (31% versus 27% and 35±16 versus 39±13 years, respectively) and aortic dissection (14% versus 10% and 38±12 versus 39±9 years) were also similar in the 2 groups. Mitral valve involvement (myxomatous, prolapse, mitral regurgitation) was less frequent in the TGFBR2 than in the FBN1 group (all P <0.05). Aortic dilatation, dissection, or sudden death was the index event leading to genetic diagnosis in 65% of families with TGFBR2 mutations, versus 32% with FBN1 mutations ( P =0.002). The rate of death was greater in TGFBR2 families before diagnosis but similar once the disease had been recognized. Most pregnancies were uneventful (without death or aortic dissection) in both TGFBR2 and FBN1 families (38 of 39 versus 213 of 217; P =1). Seven patients (10%) with a TGFBR2 mutation fulfilled international criteria for Marfan syndrome, 3 of whom presented with features specific for Loeys-Dietz syndrome. Conclusions— Clinical outcomes appear similar between treated patients with TGFBR2 mutations and individuals with FBN1 mutations. Prognosis depends on clinical disease expression and treatment rather than simply the presence of a TGFBR2 gene mutation.

7 February 2008 in Epilepsia
Verified
Journal Article
Closed access
PDF file
NBNadia Bahi‐Buisson
Nadia Bahi‐Buisson
AKAnna Kaminska
Anna Kaminska
NBNathalie Boddaert
Nathalie Boddaert
MRMarlène Rio
Marlène Rio
AAAlexandra Afenjar
Alexandra Afenjar
TBThierry Bienvenu
Thierry Bienvenu